Nancy Lin
#92,974
Most Influential Person Now
Researcher
Nancy Lin's AcademicInfluence.com Rankings
Nancy Lincomputer-science Degrees
Computer Science
#6889
World Rank
#7256
Historical Rank
Machine Learning
#3316
World Rank
#3355
Historical Rank
Artificial Intelligence
#3618
World Rank
#3669
Historical Rank
Database
#4461
World Rank
#4638
Historical Rank
Download Badge
Computer Science
Nancy Lin's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Nancy Lin Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.
Nancy Lin's Published Works
Published Works
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. (2017) (1304)
- Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. (2012) (1153)
- RECIST 1.1-Update and clarification: From the RECIST committee. (2016) (944)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- CNS metastases in breast cancer. (2004) (667)
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer (2008) (586)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
- Response assessment criteria for brain metastases: proposal from the RANO group. (2015) (553)
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. (2019) (538)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer (2009) (499)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (469)
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network (2012) (459)
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. (2008) (439)
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. (2016) (370)
- Brain Metastases: The HER2 Paradigm (2007) (370)
- Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study (2017) (350)
- Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014) (324)
- Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. (2012) (317)
- 1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
- High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer (2011) (276)
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. (2017) (274)
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020) (233)
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† (2014) (232)
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases (2019) (213)
- Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study (2017) (206)
- Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. (2008) (202)
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. (2014) (198)
- Updates in the management of brain metastases. (2016) (194)
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab (2012) (192)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. (2018) (184)
- RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. (2016) (172)
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
- CNS Metastases in Breast Cancer: Old Challenge, New Frontiers (2013) (165)
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) (164)
- Prevalence and mutational determinants of high tumor mutation burden in breast cancer (2019) (156)
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases (2011) (154)
- Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (2006) (152)
- Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. (2014) (141)
- Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib (2011) (137)
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. (2018) (137)
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies (2018) (136)
- Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. (2013) (130)
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. (2016) (130)
- Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. (2020) (127)
- The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer (2013) (124)
- Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. (2006) (121)
- The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (2014) (120)
- Advances in adjuvant endocrine therapy for postmenopausal women. (2008) (117)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (2012) (116)
- Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. (2013) (115)
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (111)
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. (2013) (109)
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. (2013) (107)
- Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer (2020) (106)
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. (2015) (102)
- Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. (2011) (98)
- HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. (2020) (96)
- HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models (2014) (96)
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype (2012) (95)
- Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM). (2020) (94)
- HSP90 as a platform for the assembly of more effective cancer chemotherapy. (2012) (90)
- Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. (2017) (90)
- Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases (2016) (89)
- Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium (2018) (88)
- Randomized trial of a physical activity intervention in women with metastatic breast cancer (2016) (86)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer (2019) (85)
- International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. (2013) (84)
- Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications (2019) (81)
- Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. (2014) (80)
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. (2017) (80)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
- Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. (2010) (78)
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2019) (77)
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. (2018) (76)
- Management of brain metastases according to molecular subtypes (2020) (73)
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 (2015) (73)
- Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. (2018) (72)
- Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer (2020) (69)
- A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer (2013) (67)
- New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors (2004) (66)
- Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers (2019) (65)
- A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer (2020) (63)
- Inhibiting HSP90 to treat cancer: a strategy in evolution. (2012) (62)
- The ethical use of mandatory research biopsies (2011) (61)
- Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases from 1985 to Today. (2020) (60)
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. (2020) (59)
- Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? (2018) (58)
- A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases (2013) (58)
- Fatal hepatic necrosis following imatinib mesylate therapy. (2003) (57)
- Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis (2020) (56)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases (2014) (55)
- Breast cancer brain metastases: new directions in systemic therapy (2013) (54)
- Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk (2020) (54)
- Subtype switching in breast cancer brain metastases: a multicenter analysis (2020) (54)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. (2020) (53)
- Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer (2019) (50)
- Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. (2010) (50)
- Targeted Therapies in Brain Metastases (2013) (50)
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer (2009) (50)
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer (2015) (48)
- Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. (2007) (47)
- Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes (2003) (46)
- Updates on the management of breast cancer brain metastases. (2014) (45)
- Breast cancer‐specific survival by age: Worse outcomes for the oldest patients (2018) (44)
- A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. (2011) (43)
- Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
- Brain Metastases : The HER 2 Paradigm (2007) (42)
- Barriers to Accrual and Enrollment in Brain Tumor Trials. (2019) (41)
- Local control after fractionated stereotactic radiation therapy for brain metastases (2014) (41)
- Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). (2016) (41)
- Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. (2019) (40)
- PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers (2016) (40)
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? (2013) (40)
- RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. (2019) (39)
- Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (39)
- Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy (2014) (39)
- Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study (2021) (35)
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions (2007) (34)
- Primary Breast Cancer Phenotypes Associated With Propensity for Central Nervous System Metastases (2007) (34)
- Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. (2014) (34)
- Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis (2016) (34)
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). (2015) (34)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (34)
- Quality of life in long-term survivors of metastatic breast cancer. (2012) (33)
- Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non–Small Cell Lung Cancer (2018) (33)
- Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. (2017) (32)
- Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer (2020) (32)
- Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. (2022) (31)
- Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer (2018) (31)
- Racial differences in outcomes for patients with metastatic breast cancer by disease subtype (2015) (31)
- Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival. (2020) (31)
- Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. (2020) (30)
- Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often? (2017) (28)
- Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation (2019) (28)
- PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling (2015) (27)
- Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. (2020) (27)
- Salvage stereotactic radiosurgery for breast cancer brain metastases (2012) (26)
- Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. (2012) (26)
- Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study (2012) (26)
- Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. (2019) (26)
- Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib (2020) (26)
- The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients (2015) (26)
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. (2009) (25)
- Heterogeneity of breast cancer and implications of adjuvant chemotherapy (2008) (25)
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. (2013) (24)
- Attitudes of patients with metastatic breast cancer toward research biopsies. (2013) (23)
- Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis (2019) (23)
- Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. (2017) (22)
- Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. (2016) (22)
- Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. (2017) (22)
- Brain metastasis: opportunity for drug development? (2012) (21)
- Targeting brain metastases in breast cancer. (2021) (21)
- Genomic Characterization of de novo Metastatic Breast Cancer (2020) (21)
- Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer (2006) (20)
- Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process. (2017) (20)
- Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases (2020) (20)
- Systemic Therapy of Central Nervous System Metastases of Breast Cancer (2019) (20)
- Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers (2016) (19)
- Global challenges and policy solutions in breast cancer control. (2022) (19)
- STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022) (19)
- New insights and emerging therapies for breast cancer brain metastases. (2012) (18)
- Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis (2021) (18)
- Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center (2014) (18)
- Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. (2014) (17)
- Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer (2013) (17)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. (2008) (16)
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update (2022) (16)
- Novel approaches to advanced breast cancer: bevacizumab and lapatinib. (2007) (16)
- How we treat HER2-positive brain metastases (2021) (16)
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (2022) (16)
- Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. (2016) (15)
- A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases (2019) (15)
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer (2013) (15)
- Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. (2020) (15)
- Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States. (2018) (14)
- Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. (2008) (14)
- Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. (2011) (14)
- Prospective clinical experience with research biopsies in breast cancer patients (2013) (13)
- Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab (2016) (13)
- Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States (2018) (12)
- Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. (2021) (12)
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). (2020) (12)
- TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (2010) (11)
- LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY (2019) (11)
- Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond (2020) (11)
- Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases (2019) (11)
- Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. (2021) (11)
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary. (2018) (11)
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? (2013) (11)
- Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer (2021) (10)
- Integrative multiomics-histopathology analysis for breast cancer classification (2021) (10)
- Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. (2017) (10)
- Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care (2022) (9)
- Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study (2020) (9)
- Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center (2020) (9)
- Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. (2018) (9)
- EMBRACE, eribulin, and new realities of advanced breast cancer (2011) (9)
- Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? (2010) (9)
- Presentation of breast cancer in young women. (2016) (8)
- Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study (2015) (8)
- Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. (2018) (8)
- Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis (2022) (8)
- Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. (2022) (7)
- Tumor subtypes and survival in male breast cancer (2021) (7)
- Dose density in breast cancer: a simple message? (2005) (7)
- Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases (2022) (7)
- Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer (2022) (7)
- Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. (2015) (7)
- Management and outcomes of men diagnosed with primary breast cancer (2021) (7)
- Better treatments needed for breast cancer brain metastases. (2015) (7)
- Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center (2015) (6)
- Combination inhibition of PI 3 K and mTORC 1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER 2-positive breast cancer brain metastases (2016) (6)
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
- Optimal use of aromatase inhibitors: to lead or to follow? (2007) (6)
- Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. (2021) (6)
- Brain metastases in HER2-positive breast cancer. (2013) (5)
- Measuring opportunities to improve timeliness of breast cancer care at Dana-Farber/Brigham and Women's Cancer Center. (2014) (5)
- Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. (2019) (5)
- Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis (2020) (5)
- Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab? (2012) (5)
- Voxelwise single‐subject analysis of imaging metabolic response to therapy in neuro‐oncology (2014) (5)
- Aggressive Subsets of Metastatic Triple Negative Breast Cancer. (2020) (5)
- Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases. (2019) (5)
- Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry (2021) (5)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (5)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (5)
- A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics. (2022) (5)
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis (2020) (4)
- Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study (2022) (4)
- Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. (2020) (4)
- Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials. (2013) (4)
- Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. (2011) (4)
- Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM) (2022) (4)
- Genomic features of rapid versus late relapse in triple negative breast cancer (2021) (4)
- Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. (2016) (4)
- TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer. (2011) (4)
- The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. (2011) (4)
- Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? (2021) (4)
- p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases (2022) (3)
- In regard to Yamamoto et al. (2012) (3)
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022) (3)
- Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. (2017) (3)
- Attitudes of patients with metastatic breast cancer toward research biopsies. (2013) (3)
- Follow-Up after Breast Cancer Diagnosis (2013) (3)
- Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap. (2009) (3)
- Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer (2021) (3)
- Genomic features of rapid versus late relapse in triple negative breast cancer (2021) (3)
- 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer (2022) (3)
- Factors associated with late risks of breast cancer-specific mortality in the SEER registry (2021) (3)
- Genomic landscape of de novo stage IV breast cancer. (2019) (3)
- Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. (2016) (3)
- Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). (2022) (2)
- Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer (2022) (2)
- Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. (2022) (2)
- Reply to H.L. McArthur et al. (2015) (2)
- Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis (2020) (2)
- Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. (2022) (2)
- Perceptions of patients with early stage breast cancer toward research biopsies (2020) (2)
- Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. (2022) (2)
- Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer (2022) (2)
- Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer (2021) (2)
- Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER (2021) (2)
- Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. (2013) (2)
- Weighing the options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer. (2015) (2)
- Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. (2018) (2)
- Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. (2022) (2)
- A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer (2021) (2)
- Machine learning predicts rapid relapse of triple negative breast cancer (2019) (2)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). (2011) (2)
- Update on managing brain metastases in breast cancer. (2018) (2)
- Abstract 5257: Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd) (2022) (2)
- Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer (2019) (2)
- Reevaluating the role of antibody drug conjugates in the treatment of patients with brain metastases. (2020) (2)
- Attitudes of patients with metastatic cancer towards research biopsies (2018) (2)
- Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. (2017) (2)
- The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer. (2022) (2)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (2)
- Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models (2021) (2)
- 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) (2020) (1)
- Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis (2022) (1)
- Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study (2023) (1)
- The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342. (2004) (1)
- Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer (2022) (1)
- CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION (2018) (1)
- Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy (2022) (1)
- Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial (2020) (1)
- Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis (2019) (1)
- Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan (2023) (1)
- Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). (2014) (1)
- Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program (2021) (1)
- A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer (2020) (1)
- Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (2013) (1)
- CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12 (2021) (1)
- Incidence proportion and prognosis of leptomeningeal disease among patients with breast versus non-breast primaries. (2022) (1)
- Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer (2021) (1)
- Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with trastuzumab. (2011) (1)
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study (2012) (1)
- A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. (2014) (1)
- THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES (2019) (1)
- Abstract P2-13-05: Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC) (2022) (1)
- Reply to V. Pitini et al. (2013) (1)
- Using Quality Improvement to Increase Access to Palliative Care. (2020) (1)
- Abstract OT2-3-06: A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic breast cancer. (2012) (1)
- Abstract OT-09-10: A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (2021) (1)
- Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer (2022) (0)
- 46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES (2020) (0)
- Leptomeningeal Disease in Breast Cancer: Pre-Treatment Prognostic Factors and Outcomes. (2021) (0)
- Utilization and patient characteristics for the trastuzumab originator, biosimilars, and other HER2 inhibitors in the United States. (2021) (0)
- Use of discard pleural fluid in molecular research (2012) (0)
- CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer (2022) (0)
- Survival in male breast cancer over the past three decades. (2022) (0)
- Advances in HER2-Positive Breast Cancer (2013) (0)
- Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science–Based Study (2022) (0)
- HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (2011) (0)
- Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) (2021) (0)
- Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care: A Protocol using the Dynamic Adaptation Process. (2021) (0)
- Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer (2019) (0)
- Abstract P6-05-05: Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC) (2023) (0)
- Response to Letter to Editor. (2020) (0)
- Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast Cancer (MBC) (2023) (0)
- Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast1 (2022) (0)
- Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer (2023) (0)
- Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction. (2014) (0)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (0)
- Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. (2023) (0)
- Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition. (0)
- Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer (2023) (0)
- Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM) (2023) (0)
- Integrative multiomics-histopathology analysis for breast cancer classification (2021) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- Abstract P2-10-01: Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with triple-negative breast cancer (2022) (0)
- Abstract P4-02-09: Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial (2023) (0)
- Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium (2019) (0)
- Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer (2018) (0)
- Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. (2022) (0)
- SYST-06. PHASE II TRIAL OF PAXALISIB (GDC-0084) IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM) (2021) (0)
- NEIM-04. PROSPECTIVE STUDY OF SCREENING MRI OF THE BRAIN IN PATIENTS WITH METASTATIC OR INFLAMMATORY BREAST CANCER (2021) (0)
- Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases (2022) (0)
- Reply to Garcia J. et al. (2017) (0)
- TITLE: Sensitive detection of minimal residual disease in patients treated for early- 1 stage breast cancer 2 (2020) (0)
- Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings (2022) (0)
- OP-JNCI200081 1..5 (2020) (0)
- Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer (2023) (0)
- Abstract PD7-07: Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis (2023) (0)
- Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Correction to: Factors associated with late risks of breast cancer‑specific mortality in the SEER registry (2021) (0)
- Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors (2022) (0)
- TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM) (2019) (0)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (0)
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (0)
- Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases (2021) (0)
- Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer (2022) (0)
- P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab (2018) (0)
- Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers Running title: Antitumoral activity of anti-HER2 ADCs in lung cancer (2020) (0)
- Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer (2022) (0)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
- Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition. (2020) (0)
- Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases (2020) (0)
- Genomic profiling of breast cancer brain metastases reveals targetable alterations. (2020) (0)
- Reply to J. Wei et al. (2021) (0)
- Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer (2022) (0)
- Project ADAPT: Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care: A Study Design (Preprint) (2021) (0)
- Abstract PD7-05: Survival of patients with brain metastases at initial breast cancer diagnosis over the last decade (2023) (0)
- NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION (2020) (0)
- Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies (2018) (0)
- Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (0)
- Multidisciplinary Management of Brain Metastasis from Breast Cancer. (2023) (0)
- Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. (2023) (0)
- Abstract 3874: Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC) (2023) (0)
- Abstract OT2-16-02: Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12 (2023) (0)
- Abstract PS6-13: Population-based tool to estimate residual risks of breast cancer specific mortality (BCSM) and non-BCSM (2021) (0)
- Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. (2023) (0)
- Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. (2019) (0)
- Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib (2023) (0)
- Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study (2023) (0)
- Concordance Between Outside Laboratory Immunohistochemistry Results and Fluorescence In Situ Hybridization ( FISH ) Results from a Central Laboratory (2007) (0)
- Salvage stereotactic radiosurgery (SRS) after previous whole-brain radiation therapy (WBRT) for breast cancer brain metastases: Outcomes and prognostic factors including tumor phenotype. (2011) (0)
- MLTI-16. SYSTEMIC THERAPY FOLLOWING CRANIOTOMY IN PATIENTS WITH A SOLITARY BREAST CANCER BRAIN METASTASIS (2019) (0)
- RF28 | PSUN185 The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer (2022) (0)
This paper list is powered by the following services:
Other Resources About Nancy Lin
What Schools Are Affiliated With Nancy Lin?
Nancy Lin is affiliated with the following schools: